이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Scotoma Perimetry 안구 운동 훈련 (SPOT)

2026년 9월 25일 업데이트: Kristina M Visscher, University of Alabama at Birmingham

황반 변성에서 안구 운동 전략을 정량화하고 훈련하는 새로운 방법

The proposed research is relevant to public health because a greater understanding of plasticity after central vision loss can inform new therapies for treating low vision and has potential to benefit millions of individuals suffering from low vision. The treatment of low vision is particularly relevant to the mission of the NEI to support research on visual disorders, mechanisms of visual function and preservation of sight.

Declines in vision are particularly common in older adults and thus increasing our understanding of how to cre- ate effective means of improving vision is also highly relevant to the mission of the NIA to support research on aging and the health and well-being of older people.

연구 개요

상세 설명

This proposal tests a novel 'scotoma awareness' approach to aid those with Macular Degeneration (MD). MD is the leading cause of central vision loss worldwide. MD patients spontaneously develop oculomotor strategies to overcome loss of central vision, such as developing a new peripheral fixation spot to replace the fovea (preferred retinal locus, or PRL). However, development of a PRL and the rate of success in developing one vary greatly, meaning some patients live years without making effective use of their spared vision. Recent, studies in Vision Science show that training healthy participants with gaze-contingent displays, obstructing central vision ('simulated scotoma'), leads to development of PRLs at a faster time scale than found for MD patients. Additionally, oculomotor metrics developed in our lab, are effective in characterizing individual eye movement patterns in simulated scotoma participants. The ability to describe differences in compensatory strategies in MD represents a crucial step towards individualized rehabilitative strategies, which could be further improved by accelerating PRL development. However, it is unclear whether these results can be reproduced in those with MD. It has been suggested that the visible, sharp-edged occluder in the gaze- contingent displays increases scotoma awareness, thus accelerating PRL development. Many MD patients are unaware of the location of their scotoma, with some persisting to use their damaged fovea as a fixation spot. No study to date has translated the use of a simulated scotoma to promote rapid PRL development in MD patients. As a first step towards addressing individual differences in patients and examine whether Vision Science paradigms can be used as a rehabilitative tool in MD, we propose two Aims: In Aim 1 we will use a set of oculomotor metrics to characterize individual profiles of compensation. In Aim 2 we will test the effectiveness of the visible, simulated scotoma as a technique to promote the rapid development of a PRL. Patients will undergo a 'scotoma awareness' training, in which a simulated scotoma, individually tailored for each patient, will be used to help them visualize their region of vision loss. Patients will be tested on the same metrics from Aim 1 and a battery of visual and cognitive assessments before and after the 'scotoma awareness' (or control) sessions. This will enable quantification of the effect of scotoma awareness both in terms of visual abilities and oculomotor strategies, and test the hypothesis that awareness of the location and extent of retinal damage promotes fast PRL development. While challenging, the use of eye tracking techniques in patients could be highly rewarding if this scotoma awareness procedure proves to be effective. A null result would be equally informative, suggesting fundamental differences between physiological and simulated scotomas, thus providing a limit in the use of simulations of retinal damage as a framework for the study of retinal pathologies such as MD. This will provide a unique data set to help those developing interventions for central vision loss understand how approaches to visual rehabilitation, and individual differences, give rise to training outcomes.

연구 유형

중재적

등록 (실제)

21

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Alabama
      • Birmingham, Alabama, 미국, 35294
        • UAB

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Severely impaired vision in both eyes (20/100 or worse)
  • Diagnosis of Macular Degeneration
  • Light sensitivity in the macular retina that is at least 10 dB units worse than in peripheral regions, as demonstrated by a scanning laser ophthalmoscope (SLO, MAIA)
  • Medical record review indicates this disease severity level has been present for at least 2 years.

Exclusion Criteria:

  • Inability to sit still in eye tracker for extended periods
  • Inability to visualize iris on video eye tracker
  • Bilateral retinal scotomas larger than 20° diameter

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 기초 과학
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Condition 1 - 'Scotoma awareness' Training

Participants will be asked to report the emotion of an emoji face ('happy' vs 'sad') that could appear anywhere on screen. For the entire duration of the training, an explicit, sharp outlined occluder surrounding the participant's true retinal scotoma will be rendered on screen. This occluder will be generated through a gaze-contingent display. The size and the contrast of the target will change adaptively in response to the patient's performance.

In the 'scotoma awareness' training, patients will perform visual search and orientation discrimination tasks while an opaque occluder, custom-tailored to overlap each patient's retinal scotoma, is constantly presented on the computer screen.

실험적: Condition 2 - Control Training

In the control condition, participants will perform the same task as the scotoma awareness training, without the artificial visible scotoma.

The task will be performed in the control group without the visible scotoma.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change From Baseline Fixation Stability After Completion of Training at Approximately 6 Weeks and 14 Weeks
기간: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

Dispersion of fixation locations averaged across trials in which the participant used their PRL (expressed as the Bivariate contour ellipse area (BCEA) of the dispersion of fixation locations).

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Change From Baseline Visual Acuity After Completion of Training at Approximately 6 Weeks and 14 Weeks
기간: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

Score of Change in baseline visual acuity, in logMAR units after training. Measured as post-test minus pre-test.

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Change From Baseline Saccadic Re-referencing After Completion of Training at Approximately 6 Weeks and 14 Weeks
기간: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

Proportion of trials with first fixation using PRL (expressed as a % of the total number of trials). Expressed as post-test minus pre-test.

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

2차 결과 측정

결과 측정
측정값 설명
기간
Change From Baseline First Saccade Landing Dispersion After Completion of Training at Approximately 6 Weeks and 14 Weeks
기간: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

The dispersion of the end point of the first saccade (expressed as the Bivariate contour ellipse area, BCEA of the dispersion). BCEA is the area (in deg^2) of an ellipse encompassing the fixation points, as described by Crossland et al., 2011.

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Change From Baseline Latency of Target Acquisition After Completion of Training at Approximately 6 Weeks and 14 Weeks
기간: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

The mean time until target is visible outside scotoma (expressed in seconds).

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Change From Baseline Saccadic Precision After Completion of Training at Approximately 6 Weeks and 14 Weeks
기간: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

The dispersion of the end point of the saccade that puts the target outside scotoma (expressed as the BCEA of the dispersion).

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Change From Baseline Percentage of Trials That Are Useful After Completion of Training at Approximately 6 Weeks and 14 Weeks
기간: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

How often participants place the target outside of the scotoma (% of dots in Saccadic precision relative to total trials). Definition of "trials that are useful" is that the target is placed outside the scotoma at some point during the trial.

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Change From Baseline Minimal Print Size From MNREAD Task After Completion of Training at Approximately 6 Weeks and 14 Weeks
기간: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

For the MNREAD test we will primarily rely upon minimal print size (a secondary measure of acuity). MNREAD is a computerized version of the task from Mansfield et al., 1993 from Gordon Legge's lab. Participants perform the task without any simulated scotoma. Sentences are shown to participants in a standardized order, from largest to smallest. The words are read out loud. The task stops when the participant can no longer read the sentence. The number of sentences is thus a measure of how small the print can be for a participant to read it effectively. Larger number of sentences is a better minimal print size. Thus we expect that effective training will result in greater values at post-test than at baseline.

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Change From Baseline Time-to-complete Trailmaking B Subtest After Completion of Training at Approximately 6 Weeks and 14 Weeks
기간: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

We will look at time-to-complete the Trail Making B subtest, measured in seconds. Post-test minus baseline. Trailmaking B test is often thought of as a measure of executive function. The task requires ordering numbers and letters, and switching between them (e.g., Find 1, then A, then 2, then B, then 3... etc.).

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Change From Baseline Contrast Sensitivity After Completion of Training at Approximately 6 Weeks and 14 Weeks
기간: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

Measured via Robson-Pelli charts. Contrast sensitivity is a measure of what visual contrast the participant can detect. This outcome is in units of log contrast sensitivity

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2022년 11월 1일

기본 완료 (실제)

2025년 6월 4일

연구 완료 (실제)

2025년 6월 30일

연구 등록 날짜

최초 제출

2022년 7월 7일

QC 기준을 충족하는 최초 제출

2022년 7월 12일

처음 게시됨 (실제)

2022년 7월 13일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 29일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 25일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Results of the project will be submitted to the relevant repository (ClinicalTrials.gov, or Open-Science Framework) within one year of the final participant completing data collection. We expect to report participant flow by group (intervention or control), participant demographics and other baseline characteristics, outcome measures and statistical analyses, adverse events (if applicable), and limitations or caveats of our results. We also will ensure that the final protocol and statistical analysis plan are uploaded to the record.

IPD 공유 기간

Results of the project will be submitted to the relevant repository (ClinicalTrials.gov, or Open-Science Framework) within one year of the final participant completing data collection.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ANALYTIC_CODE

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다